snowdeal logo

archives archives

{bio,medical} informatics

Friday, May 04, 2001

bookmark: connotea :: ::digg ::furl ::reddit ::yahoo::

find related articles. powered by google. GenomeWeb In Changing Times NIH, NSF Look Outdated
"The fact is the commercialization of science – capitalism if you will – is now the primary intellectual and financial source for most biomedical research in the world. Celera’s completion of the map of the mouse genome, coming on the heels of its sequencing of the human genome, both months ahead of the public efforts, underscores this shift. There has been a lot of grumbling over the fact that Celera is treating the mouse map as intellectual property. But the fact that private companies, which spend some $30 billion a year on biomedical research – three times as much as spent by NIH – want a piece of the action does not mean that medical research is stifled. On the contrary, the Celera model is another path towards progress."
redux [02.27.01]
find related articles. powered by google. The Financial Times Opinion: No price should be placed on the book of life
"Let me be frank here: my view is, and always has been, that the information in the genome is our genetic heritage and should not be profited from directly. It is not for sale. This is a pro partnership, not an anti-business, stance. We want to ensure that the entire world has equal access to the data, so that the potential health benefits are reaped by the many, rather than the few.

As Prime Minister Blair said: "The knowledge contained in the map of the human genome has the power to touch the lives of everyone on the planet." It is for precisely this reason that our commitment should be for the entire world to use this data so the benefits can be realised by all, and major killers such as malaria, tuberculosis, river blindness and leprosy will not be neglected."
find related articles. powered by google. The Economist Science and profit
"ONCE upon a time, pure and applied science were the same. Sir Humphry Davy discovered seven chemical elements, and invented the miner’s safety lamp. Louis Pasteur investigated the properties of molecules, and worked out how to stop milk spoiling. Everybody thought that was admirable. Somehow, things have changed. Today the feeling is widespread that science and commerce should not—must not—mix. There is a queasy suspicion that the process of discovery is in some way corrupted if it is driven by profit."

"Far from compromising science, profit in both these cases—the development of new medicines and the elucidation of the genome—has animated it, and directed it towards meeting pressing human needs. It is a happy marriage. Davy and Pasteur would surely have approved."
redux [04.26.01]
find related articles. powered by google. BioMedNet Scientists frequently fail to divulge industry ties, study shows
[requires 'free' registration]
"According to the first thorough investigation of scholarly journals published in 1997, only one-half of one percent of the authors revealed personal financial interests relating to their research. The study, lead by Tufts University's Sheldon Krimsky, appears in this month's Science and Engineering Ethics. A likely explanation, according Krimsky, is that journal editors do not compel uncooperative authors to report financial conflicts of interest. Many are not surprised at the findings. David Blumenthal, director of the Institute for Health Policy at Massachusetts General Hospital, said that researchers who fail to disclose the potential conflicts often "believe that they are people of integrity, and they feel they can separate their work from their financial interests."

But studies suggest otherwise, he said. For example, last year the editors of The New England Journal of Medicine wrote an apology for publishing reviews of drug therapies in spite of the reviewers' ties with the manufacturers. Scientists with ties to companies tend to write more favorable about those products, he said.

Reference: The New York Times, 25 April 2001"

[ rhetoric ]

Bioinformatics will be at the core of biology in the 21st century. In fields ranging from structural biology to genomics to biomedical imaging, ready access to data and analytical tools are fundamentally changing the way investigators in the life sciences conduct research and approach problems. Complex, computationally intensive biological problems are now being addressed and promise to significantly advance our understanding of biology and medicine. No biological discipline will be unaffected by these technological breakthroughs.


[ search ]

[ outbound ]

biospace / genomeweb / bio-it world / scitechdaily / biomedcentral / the panda's thumb / / nodalpoint / flags and lollipops / on genetics / a bioinformatics blog / andrew dalke / the struggling grad student / in the pipeline / gene expression / free association / pharyngula / the personal genome / genetics and public health blog / the medical informatics weblog / linuxmednews / nanodot / complexity digest /

eyeforpharma /

nsu / nyt science / bbc scitech / newshub / biology news net /

informatics review / stanford / bmj info in practice / bmj info in practice /

[ schwag ]

look snazzy and support the site at the same time by buying some snowdeal schwag !

[ et cetera ]

valid xhtml 1.0?

This site designed by
Eric C. Snowdeal III .
© 2000-2005